Screen Shot 2022-09-19 at 2.12.40 PM

Early identification of resistant ROIs for targeted therapy or localized ablation

Leave a Reply

Your email address will not be published. Required fields are marked *

Australian Privacy Policy AIQ's software has been cleared for clinical use under 510(k) K173444. For details, including the applicable Indications for Use, see: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=K173444